World's first annuloplasty system for mitral and tricuspid repair incorporating proprietary PolyCor(TM) and MyoLast(TM) technologies.
NEWTOWN, Pennsylvania, March 2, 2017 /PRNewswire/ -- Micro Interventional Devices, Inc(TM) [http://www.microinterventional.com/] (MID), is pleased to announce that it is the recipient of the CRT 2017 "Top Cardiovascular Innovation Award" for the company's MIA(TM) [http://www.microinterventional.com/tricuspid-valve-therapies] technology. The award was presented to Michael Whitman, MID's Founder, President and CEO, during the 20(th) annual CRT meeting on Tuesday, February 21(st).
"Receiving the 2017 'Top Cardiovascular Innovation Award' at one of the world's leading interventional cardiology conferences is an honor," said Michael Whitman. "The promising early data from our STTAR Study in the EU indicates that our MIA technology is effective in reducing annular dimensions and tricuspid regurgitation. CRT's recognition of the encouraging clinical results and the potential for MIA to provide an effective percutaneous solution for the treatment of tricuspid and mitral valve disease is a tremendous accomplishment for our team."
The MIA technology is designed to reduce annular dimensions and regurgitation during percutaneous transcatheter mitral and tricuspid repair. The annular reduction is achieved without sutures or other intervention due to the compliant, self-tensioning MIA implant incorporating the company's proprietary PolyCor(TM) anchors and MyoLast(TM) implantable elastomer.
About Micro Interventional Devices, Inc. (MID):
MID is the world leader in percutaneous transcatheter compliant fixation technology addressing unmet needs in structural heart disease.
Company Contact: Micro Interventional Devices, Inc. Katherine Whitman Product Director 215 600 1270 email@example.com [mailto:firstname.lastname@example.org] www.microinterventional.com [http://www.microinterventional.com/]
Micro Interventional Devices, Inc.
Web site: http://www.microinterventional.com/